Business
Oculis to Present at Upcoming March Investor Conference
ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully
About this update from Oculis Holding Ag
[{"type":"text","content":"ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis will be attending and presenting at the following upcoming investor conference: Leerink Global Healthcare ConferencePresenter: Sylvia Cheung, Chief Financial OfficerPresentation date and time: March 11, 2025 at 3:00pm ETLocation: Miami Beach, FL The Company will be available for one-on-one meetings during the conference. Interested investors should contact their respective representative at the sponsoring institution to request meetings. A live webcast of the fireside chat can also be accessed by visiting the Oculis website on the Events and Presentations section under Investors & Media. About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease. Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. For more information, please visit: www.oculis.com Oculis ContactsMs. Sylvia Cheung, [email protected] Investor & Media Relations LifeSci AdvisorsCorey Davis, [email protected] \nSource: Oculis Holding AG","length":4286,"tagName":"div"}]